CEL-SCI Corp (NYSE MKT LLC:CVM)

0.6625
Delayed Data
As of Jul 02
 -0.0275 / -3.99%
Today’s Change
0.54
Today|||52-Week Range
1.27
+14.03%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$74.2M

Company Description

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Its LEAPS product is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Contact Information

CEL-SCI Corp.
8229 Boone Boulevard
Vienna Virginia 22182-2623
P:(703) 506-9460
Investor Relations:

Employees

Shareholders

Mutual fund holders2.55%
Other institutional2.29%
Individual stakeholders15.17%

Top Executives

Geert R. KerstenChief Executive Officer, Treasurer & Director
Maximilian de ClaraPresident & Director
Patricia B. PrichepSecretary & Senior Vice President-Operations
Eyal TalorChief Scientific Officer
William JonesVice President-Quality Assurance

To view my watchlist

Not a member yet?

Sign up now for a free account